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ABSTRACT
This study utilizes Viable System Model (VSM) in diagnosing one 
policy implementation call Malaysian Biotechnology policy. The 
policy implementation is viewed from the innovation theory, which 
regards research and development (R&D) as the core of innovation 
commercialization, which in turn become the nucleus for a firm’s 
growth. Subsequently, the growth of firms as a group can lead to an 
industry’s development. This study conducted interviews with the 
agencies involved in the policy implementation and took advantage 
of the extensive information relating to the agencies that are available 
in the public domain, by using content analysis as the study’s 
methodology. This study enhances the understanding on the full 
use of VSM; it provides policy makers and implementers a guide in 
improving existing systems or designing new ones, while researchers 
are afforded an applicable theoretical conceptualization from a systems 
thinking perspective.
Keywords: Systems theories, systemic, Viable System Model, 
biotechnology, industry development, innovation theory.
INTRODUCTION
Systems view is a part of open systems theory, which suggests the existence of 
close relationships between a system and the elements within its environment.  It 
is a powerful tool in explaining a system in a comprehensive manner, particularly 
in its ability to capture the elements of a system’s environment into a model, thus 
the term systems or systemic perspective.  Perspectives on systems view include 
1) the living systems theory, 2) Bob Flood’s Four-Windows Approach, 3) Emery’s 
Open Systems Theory, and 4) the Viable System Model (VSM) (Barton, Emery, 
* Corresponding author: E-mail: fuaad@econ.upm.edu.my
Any remaining errors or omissions rest solely with the author(s) of this paper.
54
International Journal of Economics and Management
Flood, Selsky and Wolstenholme, 2004).  In regard to VSM, it was developed from 
the Cybernetic theories, which describe the relationship between a system and its 
environment as influencing each other, and the system being self-sufficient in its 
environment (Cybernetic, 2010; Espejo and Gill, 1997).  Building upon a number 
of organization theories, as well as recursive teorems and law of cohesion, VSM 
interprets the concept of self-sufficiency into the constructs of: complexity, variety, 
responsiveness, cohesion dan recursiveness (Beer, 1989a; 1989b). 
While there have been much interest in applying the systems models, most 
of them, including VSM, are complex and thus not easy to utilize.  VSM that has 
been applied in academic research generally explains a particular organization or 
a policy setting as systems, but previous research generally lacks documentation 
of its full utilization (e.g., Harwood, 2009; Watts, 2009; Schwaninger, 2006).  As 
such, understanding of its applications generally remains in the exclusive hands of 
systems scholars.  Consequently, this might hinder the model from being selected 
as a diagnostic or design framework in myriads of systems implementations 
within businesses and societies.  This might also deter it from being considered as 
an important theoretical conceptualization in mainstream academic research.  In 
this study, we fulfill this research gap by utilizing VSM in diagnosing one policy 
implementation, which is the Malaysian Biotechnology Policy. 
The Malaysian Biotechnology Policy was launched in 2005, and biotechnology 
has since been designated as a strategic industry within the country’s economic 
development strategy, which ultimate aim is to achieve the developed country 
status by the year 2020.  The policy has a three phased implementation plan: Phase 
1 (2005-2010), focuses on developing the foundation that supports biotechnology 
industry’s growth.  Phase 2 (2011-2015), aims at building the industry’s capabilities 
and competencies to achieve more rapid commercialization of biotechnology 
products, while Phase 3 (2016-2020) is expected to be the achievement phase in 
which the industry transforms into an important source of economics and wealth 
creation for the country (MOSTI, 2005).  In support of this policy, the Malaysian 
government had allocated about RM2Billion (approximately USD600Million), 
with the industry was expected to contribute about 2.5% to the country’s GDP by 
the end of 2010 (BiotechCorp, 2007). 
The policy implementation is founded on nine core elements.  The first three are 
the designated sectors targeted for development, which are agriculture, healthcare, 
and industrial, while the remaining six are their vital supporting measures. 
These include building capabilities in biotechnology research and development 
(R&D), human capital, and funding, as well as providing regulatory structure, 
and establishing strategic positioning in the biotechnology market.  All these are 
to be achieved through a comprehensive government support system, including 
operating a dedicated biotechnology industry developmental agency, called Biotech 
Corporation (BiotechCorp) and various other supporting agencies.  See Appendix 
A for the biotechnology policy thrusts.  
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In modeling the biotechnology policy implementation, this study draws from 
innovation theory, which provides the scope and establishes the focus of the study. 
Innovation theory regards R&D as core to innovation commercialization.  These 
innovations become the nucleus for a firm’s development and growth.  In turn, the 
collective growth of firms in the industry can lead to an industry’s development. 
Building on this perspective, R&D services, which directly contribute to 
biotechnology innovations, are presumed to lead to an increased number of firms 
created, and drive the rapid growth of existing firms, and consequently contribute 
to the overall development of the biotechnology industry (Jacobson, 1992; Martin, 
1994; Schumpeter, 1934; 1942; Sundbo, 1998; Tornatzky & Fleischer, 1990). 
In this regard, R&D, Firm Creation/Development, and Industry Development, serve 
as the three core services in supporting the biotechnology policy implementation. 
Combining VSM with innovation theory and utilizing content analysis as its 
research methodology, this study demonstrates the full application of VSM, enabling 
enhanced understanding of its use, and contributing toward a more rapid diffusion 
of systems perspective in both research and practice.
VIABLE SYSTEM MODEL (VSM)
In VSM, complexity and variety are two important concepts.  The complexity of a 
system (system complexity) is measured by “variety”; the greater the “variety” of 
a system, the higher its level of complexity.  On the other hand, requisite variety 
is the ability of a system to absorb variety.  A system is viable (system viability) 
if it has a requisite variety that is able to respond to different types of variety 
within its environment, including threats and opportunities, whether or not they 
are anticipated.  The equilibrium between requisite variety and variety in the 
environment is determined by the objectives to be achieved by the system.  The 
greater the variety in a system’s environment, the higher is the need for requisite 
variety by the system to enable it to manage its environment.  However, variety 
within the environment can be controlled by adjusting the order of its priority 
and focusing on variety that is considered most important.  The level of variety 
can also be controlled by lowering the expected performance level of a system 
(Beer, 1989a; 1989b; Brocklesby and Cummings, 1996; Devine, 2005).
One of the key factors in VSM is its environment, which represents the 
elements outside of the system that have an influence on it. Elements in the 
environment include sources of input to the environmental scanning activities 
(intelligence function) and all groups of external users that utilize the system’s 
outputs.  Intelligence function collects information from its environment to 
provide requisite variety that helps the system to be viable in it; the function also 
disseminates information to them (Beer, 1989a; 1989b; Brocklesby and Cummings, 
1996; Leonard, 2000).  Figure 1 shows the standard VSM framework and its 
environmental elements.
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From VSM’s perspective, a system is composed of several subsystems, and 
each of these subsystems in turn has its own subsystems; this structural chain ends 
with a single person in the organization.  Each subsystem has its own level of 
complexity which is measured by variety, and each needs requisite variety when 
providing appropriate responses to external stimuli.  A viable system requires 
subsystems, which are also viable, and vice versa.  This condition is described as 
recursiveness.  Related to recursiveness is the concept of cohesion, which refers to 
the integrated relationship between a system and its subsystems, with the subsystems 
acting as a group to ensure they support the system’s operation in accordance with 
the internal state of the system and its environment (Espejo and Gill, 1997; Espejo, 
Bowling, and Hoverstadt, 1999; Leonard, 2000).  Table 1 provides the summary 
of descriptions of these concepts.
Table 1 Definition of concepts in VSM
No. Concepts in VSM Definition
1 Variety The elements (situations) within a system as well those 
surrounding it
2 Complexity The number of variety in the system
3 Requisite variety The level of variety within a system that allows it to manage 
the level of complexity in its environment
4 Responsiveness The ability of the system to provide appropriate and timely 
feedback to its environment
5 Cohesiveness The integrated relationship between the system and its 
subsystem in which each subsystem assists the system to 
properly respond to its changing environment
6 Recursiveness The concept in which a viable system is supported by viable 
subsystems in which each subsystem is a miniature viable 
system itself
VSM defines that a system operates five basic functions to meet parts of system 
viability requirement: System 1 (implementation), System 2 (coordination), System 
3 (control), System 4 (intelligence) and System 5 (policy making) (Espejo and Gill, 
1997; Schwaninger, 2006).  System 5 acts as a policy making function to the system, 
while System 4 scans internal and external activities.  It then makes assessment, 
structures problems and opportunities originating from the environment and the 
internal system, and disseminates this information to System 5.  As shown in Figure 
1, System 4 in a viable system interacts with System 5 and its environment; it also 
helps communicate policy-related information to System 3, which then passes the 
information directly to management units of System 1 (implementation function). 
System 3 also controls the functional stability of System 1, which generates product 
and/or services based on the objectives of the system.  System 3* is the functional 
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entity that collects and distributes information from operating units directly to 
System 3.  Moreover, it disseminates additional information from System 3 to the 
operating units without going through each of their functional management units. 
System 2, on the other hand, coordinates the functions of management units in 
System 1.  In short, all five functions are connected to each other through mutual 
flows of information.  Similarly, the flows of information between higher order 
system and its subsystems are also mutual.  Systems 2, 3, 4, and 5 are generally 
referred to as meta systems (Brocklesby and Cummings, 1996; Devine, 2005; 
Leonard, 2000; Espejo & Gill, 1997). 
System 1 has two components, namely the management units, which oversee 
the activities of the operating units, which are illustrated as square boxes, and the 
operating units, which directly produce the products and services of the system, 
shown in the form of the oval shapes in Figure 1.  Each management unit (square 
box) in Subsystem 1 reports directly to System 3, as well as provides and receives 
information from System 2.  To ensure that the system is viable, the operating units 
gather information relevant to their consumers and external stakeholders, and in turn 
provide information about itself to interested groups in the environment (indicated 
by a line of relationship between an operating unit and the environment).  This 
intelligence activity provides input (key information) relevant to their respective 
management unit.  The full description of the lines and forms in VSM is tabulated 
in Table 2.
Applications of VSM in the literature have mainly focused on explaining the 
specific functions of a system, its meta systems, or the external environment of a 
firm, with few documentations of its full usage.  For example, Watts (2009) mainly 
analyzes the control and communication function of a policy-networks system, 
while Harwood (2009) examines the industry structure.  Others generally emphasize 
on the meta systems, with only minimal treatment on either the implementation 
subsystems or their relationships with the environmental elements (Schwaninger, 
2006).  The general absence of VSM’s full application from the systems thinking 
literature reduces the potential of its usage in highlighting problems and generating 
potential solutions systemically, which are the main elements of its philosophy. 
This is the research gap that the study intends to fulfill.
As VSM is a general model for diagnosing and designing a viable system, its 
application requires the use of relevant theoretical perspectives in support of data 
explanation and interpretation.  In this study, we view the biotechnology policy 
implementation from the innovation theory perspective, which strengthens the VSM 
conceptualization of the policy implementation system.  Innovation theory generally 
views R&D as the core source of innovation commercialization.  Particularly the 
Schumpeterian perspective, the innovation theory emphasizes the need for firms 
to be innovative.  In fact, innovating is equated to strategizing, and it is achieved 
through the firms’ entrepreneurial act, which is the ability of firms to identify and 
develop opportunities to produce new products/services or to integrate them in 
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their processes or systems that not only benefit the customers but also bringing in 
profits to the firms.  This capability to innovate could lead to high growth of firms 
(firm development) and rapid development of industries (industry development). 
In turn, high growth of firms and industries, which promote economic development 
in a society, benefit both the consumers and businesses (Jacobson, 1992; Khairul 
Akmaliah & Mohd Fuaad, 2008; Martin, 1994; Shane & Venkataraman, 2000; 
Schumpeter, 1934; 1942).  Thus, building on this Schumpeterian-innovation 
perspective, the biotechnology policy implementation subsystem is categorized 
Note: Subsystem 1, 2, 3 = Subsystems to SYSTEM 1; Operating Units = Operating Units for each 
Subsystem. 
Source:  Beer (1981); Espejo and Gill (1997)
Figure 1 Viable system model
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into services of R&D, Firm Creation/Development, and Industry Development. 
The categorization of these activities is also in line with the approach taken by the 
Malaysian government in allocating resources to the relevant agencies for programs 
or projects related to the biotechnology policy implementation. 
Table 2 Definition of forms and lines in VSM
No. Concepts in VSM Definition
1 Reciprocal lines among 
System 5, 4, 3, 2 and 1
Authority-based information flow.
2 Reciprocal lines between 
System 4 and the 
environment
The flows relate to the gathering and dissemination 
of information from the system to its environment 
and vice-versa.
3 Triangle Coordination or Audit function
4 Lines with arrows that 
connect  management  
units with System 3
The flow of authority between System 3 and the 
management units in System 1.  Authority flows 
describe the flows of financial allocation and 
application from subsystems to top management.
5 Lines that connect the 
operating units with  
System 3*
The flow of information is non-authority based - a 
two-way flow of information between operational 
units and audit functions without going through each 
management unit
6 Square box Management units in the high-level system and 
subsystems
7 Oval shape Operating unit for each subsystem
8 Curve lines between 
operating units
Flow of information, which is not related to 
authority that happened among the operating units, 
and is needed to ensure overall cohesiveness of 
system viability.
9 Reciprocal lines between 
square and oval boxes
Authority-based information flow, which indicates 
reports by operating units to the management unit and 
instructions they received from the management unit.
10 Reciprocal lines between 
operating units and 
environment
Flows relate to the gathering and dissemination 
of information from /to the environment to/from 
operating units.
RESEARCH METHODOLOGY
The nature of the data on the biotechnology policy implementation, which were 
collected from the published sources in the public domain, as well as through direct 
interviewing of the agencies, are mainly available in textual forms.  This warranted 
a research methodology that can address the need to analyze volumes of text-based 
data.  Therefore, content analysis methodology, which is one of the empirical 
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techniques in gaining in-depth understanding of a phenomena through analyzing 
textual data, was utilized as our research approach (Krippendorff, 2004; Duriau, 
Reger, and Pfarrer, 2007; Stemler, 2001; Mohd Fuaad and Khairul Akmaliah, 
2010).  In using content analysis as a methodological procedure, we adapted the 
six important questions outlined by Stemler (2001), which are developed based 
on Krippendorff (1980), to ensure the study’s reliability and validity.  They are: 
a) which data are collected and analyzed? b) how are they defined? c) what is 
the population from which the data are drawn? d) what are the contexts that are 
relevant to the data being analyzed? e) what are the boundaries of the analysis? 
and f) what is the target of the inferences? 
Data that were collected are those on the functions of all agencies and 
institutions involved in the implementation of biotechnology policy as well as 
their environment.  They, as a whole, formed the study’s context and boundary. 
The data were gathered through direct interviewing with the agencies involved 
in the biotechnology policy implementation and via extensive research on their 
information in the public domain, mainly from the Internet.  The latter are those 
classified as official data, including published policy papers, texts of ministers’ 
speeches, agencies and institutions’ technical reports, communication papers and 
brochures, and websites.  This was done to ensure their authenticity and accuracy, 
which is an important step in ensuring data reliability and internal validity of the 
findings.  The gathering of data began in March 2010, and it was completed on 
the 31st of August, 2010. 
Since all data gathered are factual, rather than perceptual, problems of data 
ambiguity and improper coding were significantly reduced.  Moreover, taking only 
the factual data addresses the challenges of data instability, which relate to biases in 
making data interpretations.  This procedure, which also allows the reproducibility 
of the study’s findings (Stemler, 2001) contributes toward ensuring internal validity 
of the study.  These steps within the data collection and analysis addressed the first 
five of the Stemler-Krippendorff’s (2001) procedures outlined above. 
The sixth and final Stemler-Krippendorff’s (2001)’s procedure involved 
mapping the gathered data onto the structure of VSM.  The construction of the 
data onto VSM allowed us to draw accurate conclusions regarding the functions 
of the agencies and institutions and their existing relationships and interactions. 
VSM structure also indicates the relationships between the biotechnology policy 
and the actors in its related environment.  Such application of VSM framework 
demonstrates one approach toward VSM application, which provides important 
implications to the policy’s stakeholders and researchers. 
FINDINGS
The first part of the findings section discusses the meta systems of the biotechnology 
policy implementation, which are Systems 5, 4, 3, and 2.  The functions and list 
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of agencies and institutions in the meta systems are presented in Figure 2 and 
elaborated in Columns C and D in Table 3.  The grouping of the agencies in Column 
D corresponds to their functions outlined in Column E.  The grouping further 
emphasizes the important functions performed by these agencies. 
The second part of the findings section presents the study’s outcome on System 
1, which is the implementation function.  The implementation of the biotechnology 
policy is divided into three subsystems.  For each subsystem, information regarding 
the agencies involved are discussed in Table 4 (Column C) and they are grouped 
into those that directly contribute to the operations of the subsystem and those that 
provide supporting services to the operating agencies. 
The third part of the findings section presents the environmental elements of the 
biotechnology policy implementation.  These include elements in the environment 
of System 4, and Subsystems 1, 2, and 3.  The environmental elements of the 
Subsystems 1, 2, and 3 are summarized in Column D of Table 4.  In the final 
part of the findings section, the study discusses the monitoring function and the 
relationships that exist among the operating units.
THE META-SYSTEMS OF BIOTECHNOLOGY POLICY 
IMPLEMENTATION (POLICY MAKING, INTELLIGENCE, 
CONTROL AND COORDINATION) 
System 5: Policy Making
The meta-systems of biotechnology policy implementation (as shown in Figure 2) 
include the functions of Systems 5, 4, 3, and 2.  VSM considers the agencies and 
institutions within this systemic level as major players of the policy implementation. 
System 5 includes 1) the Biotechnology Implementation Council (BIC), a 
ministerial level policy making committee chaired by the Prime Minister; 2) the 
National Innovation Council (NIC); and 3) Ministry of Science, Technology and 
Innovation (MOSTI) and the Ministry of Finance (MOF).  MOF and MOSTI are 
the lead ministries in the policy making function mainly because the former is the 
centralized treasury for government projects, while the latter is the key operation 
agency for biotechnology development in the country.  In addition to MOSTI and 
MOF, seven other ministries are also involved in the policy making activity, with 
their ministers participating as members in BIC.  These ministries are: 1) Ministry of 
International Trade and Industry (MITI); 2) Ministry of Agriculture & Agro-Based 
Industries (MOA); 3) Ministry of Plantation Industries and Commodities (MPIC); 
4) Ministry of Domestic Trade, Co-operatives and Consumerism (MDTCC); 5) 
Ministry of Natural Resources and Environment (MNRE); 6) Ministry of Health 
(MOH); and 7) Ministry of Higher Education (MOHE).  The Prime Minister and 
Deputy Prime Minister are also members of BIC.  This means that the Prime 
Minister’s Department is member of BIC (BiotechCorp, 2010).
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Note: See Tables 3 and 4 for the full description of the functions of institutions, working groups, and 
Operations Units  that make up the subsystems;  List of abbreviations in this figure and throughout the 
paper are given in Appendix B.  The symbol “?” indicates absence of the monitoring function, while 
symbol ?* indicates absence of intelligence in one of the operating units, which is R&D subsystems; 
Subsystems 1 and 2 have intelligence function. ** Agencies in boldface indicate their coordination 
role.  Source: See sources of Table 3.
Figure 2 Meta systems of biotechnology policy implementation 
program from VSM perspective
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The appointment of these ministers in this committee suggests the important 
roles of their ministries in the biotechnology policy implementation.  In fact, 
the function of each ministry corresponds with the nine thrusts specified in the 
Biotechnology Policy.  MPIC, MOA, MOH and MNRE are the anchor ministries 
in the biotechnology policy implementation as they are directly involved in the 
three biotechnology thrust sectors, while the other five ministries are their direct 
supporters.  Appendix A shows the connections amongst the biotechnology policy 
thrusts and the involvement of the respective ministries.
The NIC is chaired by the Prime Minister and the Deputy Prime Minister 
serves as the deputy chairman, thus, both are the council’s core members.  Another 
important member is the Minister in MOSTI, while other members include the 
heads of various ministries and representatives from industries, non-governmental 
organizations (NGOs), professional bodies, as well as institutions of higher 
educations.  NIC is responsible for developing the framework and coordinating 
innovation development efforts in Malaysia.  This involves planning, coordinating, 
and monitoring the implementation of the National Innovation Policy, which 
includes the Biotechnology Policy (NIC, 2010).  In this respect, NIC functions as 
the policy maker in the biotechnology policy implementation system.  Tables 3 and 
4 provide the summary of VSM functions in the implementation of biotechnology 
policy and agencies involved in each function.
System 4: Intelligence 
The intelligence function is carried out by System 4, which among others, comprises 
NIC and International Advisory Panel (IAP).  NIC is responsible for formulating 
overall innovation framework of the country, and thus it gathers information on all 
aspects of innovation in Malaysia which are to be utilized in formulating relevant 
innovation policies, including the Biotechnology Policy.  IAP acts as an advisory 
council to the biotechnology policy implementation, specifically BIC, which 
serves as the policy maker, and also advises BiotechCorp on similar relevant issues 
(BiotechCorp, 2010).  Another unit under System 4 is a division of MOSTI’s, the 
National Biotechnology Division or BIOTEK.  It was formed in 2005 and evolved 
from one of MOSTI’s department, the National Directorate of Biotechnology which 
was established in 1995 (Technology Business Review, 2009).  The creation of 
this directorate is a part of the incremental biotechnology industry development 
initiatives which began in 1984.  Since then, the biotechnology industry was given 
more focus and the amount of monetary allocation for the industry continued to 
increase.  This finally led to the launching of the Biotechnology Policy in 2005 
(Saridan, 2007).
BIOTEK serves as a secretariat to the BIC and maintains information on 
the discourses of the ministries involved in BIC, which indicates that it performs 
the coordinating role in the intelligence function.  BIOTEK is responsible for 
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coordinating, monitoring and updating the documents for Biotechnology Policy 
Paper and Biotechnology Implementation Blueprint, which means that it functions 
in the coordinating and controlling roles for System 4, shown in boldface in Figure 
2.  This information perhaps serves as input for the formulation of Biotechnology 
Policy which is carried out by BIC.  BIOTEK is also responsible for promoting 
public awareness and creating understanding of biotechnology, and thus plays the 
role of the public relations office to the overall implementation of the biotechnology 
policy (BIOTEK, 2010).  All these underscore BIOTEK’s involvement in the 
intelligence function.
The Malaysian Science and Technology Information Centre (MASTIC), 
a division of MOSTI, is also involved in the intelligence efforts.  This unit is 
responsible for performing the intelligence function of MOSTI, specifically the 
one that relates to Science and Technology (S&T) policy, which includes the 
Biotechnology Policy.  It collects, disseminates, and links the relevant information 
to its major stakeholders who are policy makers, research fund providers, 
researchers, as well as users and developers of research results (MASTIC, 2010). 
MASTIC operates an integrated portal called Knowledge Resource for Science 
and Technology Excellence, Malaysia or KRSTE.my.  This portal comprises 
MASTICLink, which is a meta-database for important information on S&T policy, 
and MyMDANA, which is a portal that gathers and provides information regarding 
funds managed by MOSTI (MyMDANA, 2010).
The Malaysian Industrial Development Authority (MIDA), an agency under the 
Ministry of International Trade and Industry (MITI), on the other hand, is tasked to 
directly promote the Biotechnology Policy initiatives as well as incentives offered 
under the policy’s BioNexus Program at the international level.  This promotion 
is carried out in collaboration with BiotechCorp with the intention of persuading 
foreign companies to set up their biotechnology businesses in the country (MIDA, 
2010; 2006).  BiotechCorp and MOSTI also play a major role in promoting the 
Biotechnology Policy initiative by organizing BioMalaysia, an annual international 
biotechnology conference and exhibition.  This conference hosts IAP meeting, and 
consists of BioInno Awarding ceremony, multiple conference tracks, workshops, 
meetings, and networking events (BioMalaysia 2010, 2010).  BiotechCorp and 
MOSTI also collaborates in promoting the Malaysian biotechnology industry, albeit 
reciprocally, by attending and organizing conferences and dialogues with potential 
international partners to promote Malaysian biotechnologies abroad for undertaking 
to interested parties, and attracting foreign companies to establish businesses in the 
country (Iskandar Mizal, 2009).  Therefore, MIDA, MITI, MOSTI and BiotechCorp 
are part of the intelligence function. 
Another agency that plays a role in the intelligence function (System 4) is 
the Malaysian Industry-Government Group for High Technology (MIGHT), a 
think-tank that is responsible for conducting studies, which findings are utilized 
in formulating the Biotechnology Policy.  MIGHT was formed in 1993 and its 
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members are representatives from the public and private sectors (MIGHT, 2010). 
It gains visibility mainly through its involvement in the Multimedia Super Corridor 
(MSC) program, which is an IT industry development policy that began in 1996, 
10 years before the commencement of the Biotechnology Policy.  MIGHT supports 
MOSTI in promoting Biotechnology Policy to business communities, thus, it 
provides the policy with a link back to its environment, and highlights its role in the 
intelligence function.  The Economic Planning Unit (EPU), a unit under the Prime 
Minister’s Department (PMD), is responsible for conducting government research 
relating to industry development as well as monitoring and evaluating government 
development programs.  It also disseminates relevant information regarding these 
development programs to the general public through its reports.  Thus, it is directly 
involved in the intelligence functions of the policy (EPU, 2010).
System 3: Control
This stage involves the participation of MOSTI’s BIOTEK, MOF, BIC, EPU and 
Accountant General’s Department (AG).  BIOTEK is responsible for reviewing 
and evaluating the progress and development of the biotechnology industry with 
regards to Biotechnology Policy and Biotechnology Implementation Plan (BIOTEK, 
2010).  Therefore, BIOTEK plays an important role in monitoring the functions of 
System 1 of the biotechnology policy.  The operation of BiotechCorp, even though 
it is a subsidiary of MOF, is under the purview of MOSTI.  BiotechCorp’s sister 
company, InnoBiologics (InnoBio), has a similar ownership and reporting structures 
as BiotechCorp.  This indicates that both MOSTI and MOF act as controlling entities 
(System 3) in all implementation activities involving BiotechCorp and InnoBio. 
BIC also governs BiotechCorp’s activities, and therefore serves as a control function 
in the biotechnology policy, which has direct involvement of BiotechCorp. 
Resource allocation for government project and programs, including for 
biotechnology policy implementation, requires approval from EPU.  Justification for 
the project proposal approval by the EPU is based on relevant programs and policies. 
EPU, which is responsible for evaluating all government development programs, 
also performs the control functions for the biotechnology policy implementation 
(EPU, 2010).  Once approved by the EPU, the proposal is send to the treasury 
(MOF) for further consent.  MOF, particularly through its AG, is the controlling 
authority for all treasury-related projects undertaken by all government agencies 
within the biotechnology policy implementation program.  The AG generally 
advises the decision makers in the government agencies in relation to accounting 
and finance.  AG controls the biotechnology policy implementation through its 
function in designing, developing, and implementing government accounting 
system.  Account statements for all implementers of the biotechnology policy 
are revised at the end of each accounting year as a part of audit procedure being 
implemented in the country’s accounting system (AG, 2010). 
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System 2: Coordination 
The function of System 2, which is the coordinating function of System 1, has two 
categories.  The first category involves the efforts by BIC, which acts as a platform 
for inter-ministerial forum.  This coordinating function is critical because the 
functions of the subsystems in System 1 are performed by many ministries.  As all 
of the agencies and working groups are under the ministries that are represented in 
the BIC, BIC plays the overall coordinating function for the policy implementation 
(BiotechCorp, 2010).  This also makes BIC as the lead committee in the system 
coordination, as shown in boldface in Figure 2.  The second category includes 
EPU and Coordination Unit (ICU) of the Prime Minister’s Department.  EPU is 
involved in coordinating the implementation of the biotechnology policy, as it 
is responsible for managing all government development programs through its 
involvement in the country’s five-year development planning and the preparation of 
necessary documentation (EPU, 2010).  Coordination of the biotechnology policy 
implementation also involves ICU, whose responsibilities includes coordinating, 
monitoring and evaluating government policies and development projects, of which 
biotechnology policy implementation is one of them (ICU, 2010).
Relationships of Meta-Systems (Policy Making, Intelligence, Control 
and Coordination) within the Biotechnology Policy Implementation 
As shown in Figure 2, there is a direct flow of information from one system in the 
meta-system to the other, shown by the arrows going in and out between them. 
For example, in the case of MOSTI, its function in intelligence is either directly 
performed through BIOTEK or BiotechCorp, to serve as input into its policy making 
function.  The information collected via the intelligence function are then directly 
disseminated to its controlling function.  MOSTI is also directly involved in the 
implementation function, by its participation as an entity in all implementation 
activities involving BiotechCorp and InnoBio.  Another example of relationships 
that exist within the meta-systems is that of MOF, which gathers intelligence 
through its subsidiary, BiotechCorp, and serves as the controlling agency through 
its Accountant General’s Department (AG).  MOF also indirectly controls the 
implementation activities via its two subsidiaries, BiotechCorp and InnoBio, and 
directly linked to the coordination function through the ICU. 
SYSTEM 1: BIOTECHNOLOGY POLICY IMPLEMENTATION
To achieve the objectives of the biotechnology policy implementation, the activities 
and programs implemented are divided into three major activities: 1) research 
and development (R&D), R&D commercialization/technology development/
acquisition/transfer services; 2) firm creation/firm development services; and 
3) industry development services.  VSM modeling of System 1 is shown in detail 
in Figure 3. 
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Biotechnology Policy Implementation from a Systems Perspective 
Subsystem 1: R&D Services
Subsystem 1 involves services of a) R&D, and b) R&D commercialization, 
technology development, acquisition, and transfer within the biotechnology 
field.  The latter activity is defined as a set of activities that will lead to the 
commercialization of biotechnology products or services.  Many agencies and 
institutions are involved in this subsystem in various ways, and they are categorized 
into two groups 1) R&D services (Group 1.1); 2) their supporting agencies 
(Group 2.1). 
In Group 1.1, biotechnology R&D activity is carried out by the three 
designated biotechnology institutes—Malaysian Institute of Pharmaceuticals 
and Nutraceuticals (IPharm), Malaysia Genome Institute (GENOMalaysia), and 
Agro-Biotechnology Institute (ABI), which are under the purview of MOSTI, 
with BIOTEK serving as the monitoring unit.  IPharm is an R&D institute for 
pharmaceuticals and nutraceuticals focusing on drug discovery and development 
(IPharm, 2010).  ABI, on the other hand, is a pure R&D and commercialization 
institute for agro-biotechnology.  It also manages R&D commercialization in 
collaboration with universities, research institutes, and industry players (ABI, 
2010).  GENOMalaysia’s focus is to discover marketable and useful tropical 
bioresources via research.  As GENOMalaysia also operates an R&D facility, 
which can be utilized by researchers, it also plays a role in biotechnology R&D 
commercialization (GENOMalaysia, 2010). 
Group 1.1 also comprises public-funded universities and government research 
institutes.  Research in biotechnology was conducted by 15 public-funded 
universities whose research spanned from simple agriculture-biotechnology to 
the more complex ones, like DNA recombinant exploitation (BiotechCorp, 2010). 
These universities receive funding from MOSTI with six of them operating a 
dedicated unit or institute for biotechnology research.  The operations of these 
universities are under the jurisdiction of the Ministry of Higher Education (MOHE), 
which means it is responsible for devising policies concerning research activities 
and output commercialization for the universities. 
Besides these public universities, 13 government research institutes conduct 
research in biotechnology (BiotechCorp, 2010).  All of them perform R&D as 
their own operations, not on the behalf of other parties.  In contrast to the public 
universities, which focus on science-based research, these research institutes mostly 
conduct applied-based research.  These research institutes include the Malaysian 
Agriculture Research and Development Institute (MARDI), Malaysian Palm Oil 
Board (MPOB), Institute of Medical Research (IMR), Forest Research Institute of 
Malaysia (FRIM), Malaysian Rubber Board (MRB), and Malaysian Cocoa Board 
(MCB).  They were well established research institutes prior to the launching of 
the Biotechnology Policy in 2005.  However, with the launching of the policy, the 
institutes intensify their research efforts and include biotechnology as one of their 
focus area (EPU, 2006). 
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Group 1.2 of the R&D services comprises fund providers and other supporting 
agencies.  MOSTI is one of the major fund providers through its administration 
of the Science Fund and the ER-Biotek Fund, which are offered to researchers in 
the public universities and research institutes.  The Science Fund is specifically 
designed to support value analysis, conceptualization of ideas as well as basic 
and applied research conduct, while the ER-Biotek Fund is an R&D and R&D 
commercialization grant.  MOSTI also manages two other grants, the Techno 
Fund and the Inno Fund, which are aimed at providing financial assistance to 
entrepreneurs/firms in their pre-commercialization activities, such as prototype 
development/commercialization, technology/IP acquisition, and pilot plant 
construction.  Techno Fund is offered to researchers in government research 
institutes and public universities, small and medium sized enterprises (SMEs) and 
large companies.  However, those in government research institutes and public 
universities are encouraged to include an industry partner in their teams, and vice 
versa.  Inno Fund, on the other hand, is offered to individuals, owners of small 
enterprises, and community groups to support commercialization of their products 
and services (MASTIC, 2010).  MOSTI is also responsible for organizing the annual 
National Biotechnology Seminar, which is a platform for biotechnology researchers, 
from private and public higher learning institutions, as well as research institutes 
in the country, to meet and exchange research ideas.  The seminar, which mainly 
involved research funded by MOSTI grants, enable a more synergistic relationship 
between the private sector and public research institutes, and aims at reducing 
redundancy and direct competition among them.  
MOF also participates directly in the Group 2.2 of R&D subsystem through 
its MOF Inc.’s two subsidiaries, the InnoBio and Malaysia Venture Capital 
Management Bhd (MAVCAP).  InnoBio is a government entity that provides direct 
consultancy and contract research (mainly in process and manufacturing) in the field 
of biopharmaceuticals to client organizations, which may include research institutes 
and biotechnology businesses, particularly pharmaceutical companies (InnoBio, 
2010).  These services, which are available to firms with or without the BioNexus 
status, contribute directly to the functions of technology commercialization and 
development.  InnoBio also contributes to technology development by conducting 
training for researchers in universities and research institutes to help them keep 
abreast with leading-edge technologies.  MOF Inc.’s MAVCAP subsidiary, Cradle 
Fund, which distributes pre-seeding and firm development funds is also one of the 
service agencies operating in Group 2.2 of Subsystem 1 (BIOTEK, 2009; Cradle 
Fund, 2010). 
BIOTEK also plays an important function in this subsystem.  Its role is to 
facilitate and coordinate the disbursements of R&D funds and technology transfer 
involving projects under its responsibilities as well as all R&D projects undertaken 
by MOSTI’s agencies.  Part of BIOTEK’s responsibility is to facilitate the 
application for patent funding, particularly for those research funded by MOSTI. 
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Technology Park Malaysia Corporation Sdn Bhd (TPM), a science park 
operator and manager, which operates an incubating facility that support R&D 
conduct, is also a supporting agency in the R&D services function.  TPM was 
formed in 1996 in conjunction with the launching of the Multimedia Super Corridor 
(MSC) Program, in which TPM is created and designated as one the anchor agencies 
in the development of IT business cluster and its areas being specified as part of 
the MSC area.  TPM’s roles has since been expanded to also directly support 
biotechnology policy when it was launched in 2005.  The biotechnology ventures 
and companies in TPM Park have access to services and facilities provided by 
TPM’s subsidiaries in various areas of expertise, including biotechnology, ICT, 
and engineering.  Specifically, a TPM’s subsidiary, called TPM Biotech, performs 
biotechnology R&D in developing and commercializing its own biotechnology-
related products.  It also offers contract R&D and manufacturing, and marketing 
services to client companies that are located within and outside of the park (TPM, 
2010; TPM Biotech, 2010). 
BiotechCorp is also involved in this subsystem as it is responsible for 
administering the Seed Fund, which is granted to companies with BioNexus status 
in support of their business startup process.  The fund pays for entrepreneurs’ 
operational costs, as well as support the development and commercialization of 
their biotechnology projects and R&D findings.  Moreover, BiotechCorp supports 
R&D Commercialization through its acquisition of a French platform technology, 
which enables biotechnology firms to generate applications related to diagnostic 
and drug delivery systems. 
The handling of the R&D commercialization process from universities to 
industries is a major function of Malaysian Technology Development Corporation 
(MTDC).  MTDC was formed in 1992 and its function was strengthened in 1996 in 
support of the earlier-launched MSC Program.  Its roles has since been expanded 
and refocused for the biotechnology policy when the policy was launched in 2005. 
In support of this policy implementation, the agency performs three major activities. 
First, it administers three university-based incubators, and second, it manages and 
organizes the Symbiosis Program.  Third, it handles the Commercialization of R&D 
Funds (CRDF), the Technology Acquisition Funds (TAF), and the Malaysian Life 
Sciences Capital Funds (MLSCF) (BIOTEK, 2009). 
The three incubators managed by MTDC act as mediums for commercializing 
inventions and technologies from local universities.  They also play hosts to firms 
that need incubating facilities to support their growth.  One of the incubators, the 
UKM-MTDC, is a dedicated site for promoting commercialization of biotechnology 
and pharmaceuticals research findings.  All MTDC’s incubator programs are 
linked to its grant programs, thus, its incubators’ tenants have preferential access 
to information on its CRDF and TAF and this improves their odds of achieving 
rapid technology development and commercialization. The UPM-MTDC 
incubator, which began as an ICT incubator, has gradually moved into hosting 
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more biotechnology ventures.  This is perhaps in line with its MTDC corporate 
unit’s more focused efforts to support biotechnology-life sciences businesses.  The 
function of MTDC Symbiosis Program is to assist in the commercialization of 
innovative technologies resulting from research activities at local universities and 
research institutes.  So far, the program involves collaborations with the Forest 
Research Institute of Malaysia (FRIM) to commercialize bio-forest technologies, 
and with UKM to bring to market biotechnology-related inventions that originated 
from the university (MTDC, 2010; RAIDAH, 2010). 
In regard to funding, MTDC’s CRDF is a grant offered to qualified researchers 
and technopreneurs to help them commercialize research findings from local 
universities and research institutes.  MTDC also supports technology development 
through its MLSCF’s biotechnology venture capital fund that it co-managed with 
Burill & Co., a San Francisco-based life-sciences merchant bank. MLSCF’s 
investments focus on both early stage and later-stage companies that meet its 
criteria, including producing highly innovative products or services in either one 
of the three focused sectors of the Biotechnology Policy, which are agriculture, 
healthcare, and industrial (MLSCF, 2010). 
Intellectual Property Corporation of Malaysia (MyIPO), an agency under 
MDTCC, provides registration services of patents, trademarks and other types 
of intellectual property (IP) indications in Malaysia, including those related 
to biotechnology products, services and processes.  It also offers advisory and 
consultancy services on IP to companies, disseminates IP information and statistical 
data, as well as conducts training programs on IP-related issues and patent agent 
examination (MyIPO, 2010; 2007; Rohazar Wati, 2007).  Therefore, in this respect, 
MyIPO provides direct support to the function of technology development, 
commercialization, transfer and acquisition.  
In regard to the management function in Subsystem 1, MOSTI and MOF play 
the key function, as the former is the lead agency that manages most government 
research funds in biotechnology, while the latter oversees all monetary allocation 
and disbursements to all the related research units.  There are also some coordinating 
activities occurring.  BIOTEK is in charge of coordinating fund applications under 
its perusal, which are the Science Fund, Techno Fund, Inno Fund and ER-Biotek 
Fund.  This suggests that BIOTEK’s activities transcend across two subsystems 
within System 1, and these include R&D, R&D commercialization, firm creation, 
and firm development.  The coordination of these funds are supported by an online 
portal called MyMDANA (MyMDANA, 2010).  BIOTEK also manages the research 
projects at three MOSTI research institutes, which are ABI, GENOMalaysia, and 
IPharm.  Moreover, it coordinates the activities of all technology transfer projects 
involving MOSTI funds undertaken under the 9th Malaysia Plan, which is a five-
year government development plan, which begins in 2006 and ends in 2010.  As the 
lead biotechnology development unit, BIOTEK also coordinates the Biotechnology 
Agency Cluster, thus directly oversees the joint activities of IPharm, ABI, and 
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GENOMalaysia with other agencies in the cluster, including InnoBio, BiotechCorp, 
MTDC, TPM and MIGHT (MOSTI, 2010b).  MOSTI is also making the effort to 
link the various R&D entities through virtual connections.  For example, MOSTI’s 
MASTIC operates KRSTE.my, which comprises MASTICLink and MyMDANA, 
thus making KRSTE.my the coordinating function for all R&D entities in Subsystem 
1 which receives funding from MOSTI.  MOHE also plays the management function 
for research conducted by public universities. 
To summarize, there are two categories of agencies and institutions in this 
Subsystem: a) the management units; and b) the operating units, which can be 
divided into R&D institutions and their related services agencies.  The operating 
units include universities and research institutes conducting science-based and 
applied R&D.  The services agencies are those that support R&D functions, such 
as: a) fund providers, such as MOSTI, MTDC, MLSCF, BiotechCorp, and Cradle 
Fund; b) those that provide research facilities, such as InnoBio, TPM Biotech, 
and GENOMalaysia; c) those involved in developing R&D talents, such as, 
GENOMalaysia and InnoBio, with BioTalent assuming the role of facilitator; and 
d) those that create conducive environment for R&D conduct, such as MTDC, 
TPM, and MyIPO.  All these functions are managed by BIOTEK, MOSTI and 
MOF, while MOHE serves as the management function for all R&D activities 
in the public universities.  Availability of these functions which covers funding, 
research facilities, talent development, as well as IP protection and development in 
Subsystem 1, suggests that there exist comprehensive supports for biotechnology 
R&D function within the biotechnology policy implementation.  The operations 
of these units are also well facilitated. 
Subsystem 2: Firm Creation/Development Services
Subsystem 2 involves services for firm creation/development, which is categorized 
into two groups of agencies: Firm Creation/Development Services (Group 2.1) and 
their supporting services agencies (Group 2.2).  In Group 2.1, BiotechCorp, which 
is created specifically as a one-stop developmental agency for the biotechnology 
industry development, is the key agency in this subsystem.  It performs the functions 
of advisor, processor and facilitator in assisting technology and firm development. 
Its services are offered through the BioNexus Program, which is a comprehensive 
support program for developing biotechnology companies.  BioNexus status is 
granted to firms that are involved in the high-end biotechnology businesses in the 
three focused areas of the Biotechnology Policy.  BioNexus companies receive many 
incentives including tax exemptions, direct funding, financing and immigration 
facilitation, human capital development and product registration/testing assistance, 
and location advisory, as well as access to expertise in the BiotechCorp network 
(BiotechCorp, 2007).  All these are to promote rapid growth of the companies and 
to encourage foreign direct investment in the biotechnology industry.  The number 
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of BioNexus status companies had grown rapidly from about 50 in early 2008 to 
more than 150 companies in early 2010.  By June 2009, most BioNexus companies 
are involved in healthcare and agro-biotechnology, while the rest is in the industrial 
and bioinformatics sector (Iskandar Mizal, 2009).  These companies are members of 
a group which is expected to contribute to the 2.5% in the biotechnology industry 
contribution to Malaysian GDP by the end of year 2010. 
Besides serving the existing BioNexus status firms, some BiotechCorp programs 
are offered to companies that have high potential to qualify for the status in the 
future.  This is in line with the expectation of the Malaysian government to increase 
the number of BioNexus companies to 185 in 2011 (Bernama, 2009).  BiotechCorp 
has also acquired a French platform technology that enables biotechnology firms 
to generate applications for diagnostic and drug delivery systems.  It also manages 
the R&D Matching Fund and the International Business Development Matching 
Fund, which are offered to firms with BioNexus status (BiotechCorp, 2010).  All 
these indicate BiotechCorp’s direct contribution to firm development. 
BiotechCorp also organizes the BioNexus Partner Program, a plan that 
provides a network of partners that offer services, equipment and facilities to 
companies with BioNexus status and other biotechnology commercial entities. 
These partners include laboratories and units within public universities, research 
institutes, government-linked companies, technology/science parks and incubators. 
Through its Triple-Helix portal, BiotechCorp maintains a database of life-sciences/
biotechnology commercialization or collaboration partners, projects/products 
for investment, patented products by Malaysian researchers, research facilities/
equipment/services, and expertise.  It also provides updated information on latest 
R&Ds and patents on biotechnology-related products by Malaysian researchers 
within the healthcare, agricultural, industrial and environmental sectors.  These 
services are specifically designed to enhance cooperation among the three key 
biotechnology players—researchers, industry, and government, and to enable 
BioNexus companies to have access to various facilities in support of their 
development (BiotechCorp, 2010). 
To enhance its BioNexus Partner Program, BiotechCorp also manages 
the BioTalent portal, which is an online site for jobseekers, students/interns, 
academicians, consultants, researchers and employers, in its support to build human 
capital capabilities in biotechnology (BiotechCorp, 2010).  It is a source for human 
resource and skills development in biotechnology industry which can be utilized 
by entities in Subsystems 1 and 2 to provide and access information.  It can be 
considered to directly supporting human resource development, thus contributing 
toward firm development.
MTDC also plays a direct part in promoting firm development as it is 
responsible for administering the MLSCF, a dedicated biotechnology venture 
capital fund (MLSCF, 2010), and TAF, which is a grant to facilitate acquisition of 
technology by companies that intend to improve their operations.  Its three business 
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incubators also function in support of firm development.  Its Symbiosis Program, 
which is a comprehensive program of technology commercialization, involves 
bringing to the market new technologies from universities and research institutes, 
and investing in human capital development, directly supports the functions of 
entrepreneurial development and firm creation.  All these indicate MTDC’s function 
in Subsystem 2. 
The TPM Science Park, which includes an incubator and an enterprise 
complex, which host technology-based companies, including those involved in 
biotechnology businesses, directly supports the development of biotechnology 
products and companies.  Its subsidiary, TPM Biotech, which provides research and 
production facilities as well as marketing services for biotechnology companies, 
also contributes directly to firm creation and development. 
In Group 2.2, SME Bank offers Biotechnology Entrepreneur Program’s loan 
to biotechnology firms, to be used in support of their firms’ development (SME 
Bank, 2010).  MOSTI is also involved in supporting firm creation and development 
through the provision of its Inno Fund and Techno Fund, which are offered to 
researchers in government research institutes and public universities, small and 
medium sized enterprises (SMEs) and large companies, in various stages of 
technology development.  Malaysia Debt Ventures Bhd. (MDV), a subsidiary of 
MOF, also has an important role in the development of biotechnology companies, 
as it offers financing to companies that have received and are in the process of 
fulfilling their customers’ product orders (MDV, 2010).  Another financing agency is 
MAVCAP, a government-owned venture capital company which began its operation 
in 2001 and is the parent company of Cradle Fund.  Cradle Fund manages the pre-
seeding grant that supports commercialization of innovative ideas including those 
in biotechnology.  Its grants include U-CIP, which is targeted toward academic 
community (lecturers, students or researchers) interested in commercializing their 
technology ideas and R&D, and CIP500 Grant, which helps entrepreneurs to move 
from seed phase to technology commercialization phase.  In combination with its 
grants, Cradle Fund provides assistance such as mentoring, advising, coaching and 
financial training.  In this regard, it directly contributes to firm creation as well as 
firm development (Cradle Fund, 2010). 
One important supporting entity in this subsystem is InnoBio, an agency, 
which provides processing and current Good Manufacturing Practice (cGMP) 
manufacturing facility for biopharmaceuticals to Malaysian biotechnology firms 
and research institutes.  This is to help its clients produce high-quality healthcare 
products at affordable prices, while enabling them to achieve compliance of their 
products with global regulatory guidelines and standards.  Therefore, InnoBio’s 
operations directly contribute to firm development.  Besides, InnoBio’s training 
for those from the industries to help them keep abreast with the latest technology 
development (InnoBio, 2010), help to develop human resource in the biotechnology 
companies, thus contributing directly to their firm development. 
80
International Journal of Economics and Management
In addition to its main activity in conducting research, GENOMalaysia is also 
involved in training and providing research labs and development facilities to other 
researchers and industry players (GENOMalaysia, 2010).  As the training contributes 
to the development of human resource in biotechnology firms, and the research 
being conducted at its platform can lead to technology being commercialized or 
adopted by existing biotechnology firms, GENOMalaysia contributes directly to 
firm creation and development. 
In regard to human resource development, MOHE is given the responsibility 
of ensuring that an adequate and qualified number of workers are available for 
firms in the biotechnology industry and that its related areas are properly developed 
(EPU, 2006).  In this respect, public universities are making important contribution 
toward firm development as they provide the graduates needed for the development 
of biotechnology firms.  MyIPO is another agency that supports firm development 
as it provides registration services of patents, trademarks and other types of IP 
indications including those related to biotechnology products, services and processes 
(MyIPO, 2010; Rohazar Wati, 2007).
BIOTEK plays a major role in facilitating and coordinating biotechnology 
R&D technology transfer, involving many agencies operating within Subsystem 
2, as well as facilitating patent applications of technologies and innovations that 
are developed using MOSTI and other government funds into the industry.  As the 
technology or the IP that is created and transferred are undertaken by entrepreneurs 
and existing firms contributes to the firm creation and/or development, it is a direct 
management function of Subsystem 2. 
Another management unit within Subsystem 2 is the BiotechCorp which is 
the coordinating function of important agencies operating within the subsystem. 
BiotechCorp’s BioNexus Partner Program requires that it manages the 
communication links among the agencies, institutions and industry players in the 
subsystem who are members of this Program.  This is done with the help of its 
Triple-Helix online portal, which assists the coordination function that transcends 
across agencies, institutions and firms within  the subsystem (BiotechCorp, 2010). 
This portal also connects Subsystem 2 to industry players (especially the BioNexus 
companies), thus providing a direct link between the subsystem and its environment. 
To summarize, there are two categories of agencies and institutions in this 
Subsystem: 1) the management units; and 2) the firm developer units and their 
related services agencies.  Firm developer units are full-service houses such as 
BiotechCorp, MTDC, MLSCF, and TPM.  Services agencies include a) fund 
providers such as MOSTI, Cradle Fund, MLSCF, SME Bank, and MDV, b) 
specialized services providers which include InnoBio (talent development, 
research and manufacturing facilities), GENOMalaysia (talent development and 
research facilities), TPM Biotech (research and production facilities), public 
universities (support for human resource development), and MyIPO (support for IP 
protection and development).  Talent development is facilitated and supported by 
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BiotechCorp’s BioTalent and Triple-Helix System.  The services agencies operating 
within Subsystem 2 are led and facilitated by BiotechCorp through its BioNexus 
Partner Program, as well as BIOTEK as the leading agency for the Biotechnology 
Agency Cluster, while MOF functions as the controller of all the agencies.  These 
information on the operating and management units of Subsystem 2 indicate that 
there are comprehensive support for biotechnology firm creation and development 
within the biotechnology policy implementation.  This support covers funding, 
research and manufacturing facilities, talent development, as well as IP protection 
and development, and their operations are also well facilitated. 
Subsystem 3: Industry Development Services
Initially, Biotechnology Policy stated that agriculture, healthcare, and industrial 
sectors would be its major thrusts for industry development.  However, 
bioinformatics was later added into the Policy’s list of focused industry.  This 
is because the sector could capitalize on the country’s existing strengths and 
infrastructures of an earlier-launched MSC Program, in which IT-multimedia 
industry is the major focus areas of development.  This shows the importance of 
resources sharing among existing institutions in supporting biotechnology industry 
development (EPU, 2006).
The agri-biotechnology sector development focuses on technologies, such as 
genetic engineering, genomics, proteomics and biopharming, as well as transgenic 
plants and livestocks.  The development of the healthcare-biotechnology sector, 
on the contrary, aims at leveraging the country’s biodiversity and local knowledge 
in traditional/complementary medicine, to develop leads for the pharmaceutical/
nutraceutical products and industry development.  Therefore, contract R&D 
of biogenerics, diagnostics and vaccines become major focus development 
areas.  Lastly, the industrial biotechnology development focuses on biocatalysts, 
bioprocessing (including biofuel) and biomanufacturing (EPU, 2006).  
The services provided for industry development comprises of Group 3.1, 
which provides direct support, and Group 3.2, which plays the supporting roles. 
BiotechCorp’s acquisition of the French platform technology, which helps BioNexus 
healthcare-biotechnology companies to generate a number of applications for 
diagnostic and drug delivery systems, has the ultimate aim of rapidly developing the 
biotechnology industry.  BiotechCorp’s planned acquisition of platform technologies 
for agriculture and industrial sectors in 2011 also reflects its aim of supporting the 
industry development (Iskandar Mizal, 2009). 
The MTDC’s Symbiosis program directly supports the development of new 
firms, and it being a host to the cluster of firms, which either operates within the 
MTDC incubators and/or those receiving grants or venture capital (MLSCF) that 
it managed, generally promotes the development of biotechnology industry.  The 
companies in this MTDC family have access to important information and are 
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linked to each other via the RAIDAH online portal (MTDC, 2010; MLSCF, 2010; 
RAIDAH, 2010). 
The TPM Science Park is another cluster program in which technology-based 
companies, including those in biotechnology, along with their supporting entities 
mainly in the form of TPM own subsidiaries, are grouped together geographically 
within the park.  The TPM Park includes an incubator and an enterprise complex, 
which together hosts both small and medium-sized companies.  TPM also has land 
for lease for the setting up of larger business operations which directly support 
the function of biotechnology industry development.  The tenants within the park 
have access to important services and facilities provided by TPM’s subsidiaries in 
various areas of expertise, including biotechnology, ICT, and engineering.  They 
also benefit from being closely located to other similar firms.  This grouping allows 
a more efficient exchange amongst the firms operating within the park (TPM, 
2010; TPM Biotech, 2010).  All these contribute directly to the development of 
the biotechnology industry. 
Industry development for biotechnology requires each of the focused 
biotechnology sectors, which are agro-biotechnology, healthcare, and industrial 
biotechnology, are developed.  One effort toward achieving this is through 
development of a biotechnology geographical-cluster in healthcare, called Bio 
Xcell.  The objective is to create a cluster of biotechnology firms in one geographical 
location by building supportive physical infrastructure and attracting established 
anchor companies to set their operations there.  This effort involves a joint land 
development project in Nusajaya, Johor, involving BiotechCorp, UEM Land (who 
is the land owner), and the Johor state government.  Bio Xcell operates a pilot 
plant facility, incubating space, shared laboratories as well as other amenities 
with a focus on the R&D and manufacturing of the healthcare biotechnology that 
companies and its employees within the park can utilize in support of their business 
operations (Bio Xcell, 2010).  Meanwhile, another geographical-based cluster is 
in development, through InnoBio’s planned biotechnology healthcare ecosystem, 
which involves construction of a Bio Innovation Centre within the vicinity of its 
existing bio-manufacturing facilities in Nilai (Bio Innovation Centre, 2010). 
Within the supporting Group 3.2, InnoBio provides contract research and 
manufacturing as well as consultancy for process and manufacturing research.  As 
more firms use InnoBio’s consultancy and manufacturing facilities, its services 
help them to grow; thus InnoBio plays an important role in supporting industry 
development.  As InnoBio also conducts training for industries, universities 
and research institutes, it also contributes to developing human capital for the 
industry, and hence contributes toward biotechnology industry development. 
GENOMalaysia, which is also involved in industry development as it provides 
training for skilled workforce in cutting-edge biotechnologies, also contributes 
to industry development.  As MOHE is responsible for ensuring an adequate 
and qualified supply of human resource in biotechnology and developing its 
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related areas (EPU, 2006), it directly functions in support of the biotechnology 
industry development.  MyIPO is also one of the agencies that directly support 
the development of biotechnology industry as it promotes the protection and 
development of IP within the industry (MyIPO, 2010; Rohazar Wati, 2007).  MIDA, 
BiotechCorp and MOSTI, which are involved in promoting the biotechnology 
industry to the business communities, also play important role in supporting the 
industry development.  
BiotechCorp is the facilitation function of Subsystem 3 through its BioNexus 
Partner Program, which members include three key biotechnology players—
researchers, government, and industry, including companies with the BioNexus 
status.  The operation of the BioNexus Partner Program is enabled by BiotechCorp 
Triple-Helix portal, which is specifically designed to enhance cooperation among 
its members.  This portal system assists biotechnology firms and relevant players 
to achieve the aim of forming and strengthening a business cluster on the selected 
focused biotechnology fields (BiotechCorp, 2010).  In this regard, BiotechCorp 
promotes the biotechnology industry development.  Moreover, BiotechCorp’s 
BioTalent portal, which is a source for human resource and skills development 
in biotechnology industry and directly contributes to the development of human 
capital, is also contributing directly toward industry development.
BIOTEK is the coordinator of all the agencies within the Biotechnology Agency 
Cluster, a virtual cluster connecting eight important agencies in the Biotechnology 
Policy implementation, which are IPharm, ABI, GENOMalaysia, TPM, InnoBio, 
MTDC, MIGHT, and BiotechCorp.  The objective of these agencies’ grouping is to 
collectively facilitate services provision amongst the agencies; and thus promoting 
a more efficient communication between the agencies, allowing them to serve 
their customers more efficiently (MOSTI, 2010b).  In this regard, BIOTEK is 
performing the function of facilitation amongst the key agencies in the industry 
development subsystem. 
To summarize, there are two categories of agencies and institutions in this 
Subsystem: a) the management units; and b) the agencies that are directly involved 
in developing biotechnology industry and their related services agencies.  Agencies 
that are directly involved in developing the industry include those that are drawn 
into the various biotechnology-related cluster programs, which are: a) BiotechCorp 
virtual cluster; b) MTDC cluster; c) TPM Science Park; d) Bio Xcell cluster; 
e) InnoBio cluster, and f) Biotechnology Agency Cluster and the agencies include 
BIOTEK, BiotechCorp, UEM Land, MTDC, InnoBio and TPM.  The services 
agencies include a) human capital developers, which are public universities, 
InnoBio, GENOMalaysia; b) specialized service providers, which include MyIPO 
(support for IP protection and development), and c) international relations and 
networks and promotion, which include MIDA, BiotechCorp, and MOSTI.  The 
provision of these agencies’ services are facilitated by BiotechCorp, through its 
BioNexus Partner Program, as well as BIOTEK as the leading agency for the 
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Biotechnology Agency Cluster, while the development of human capital by the 
public universities are facilitated by MOHE.  The agencies within this Subsystem 
3 are under the purview of MOF. 
Environmental Elements of the Biotechnology  
Policy Implementation
The biotechnology policy system’s environment is handled at various systemic levels 
by relevant agencies.  In this paper, we discuss the environments at the corporate 
level and systemic lower level for each subsystem.  These are environments of 
System 4, as well as Subsystems 1, 2 and 3.  These environmental elements are 
summarized in Columns D and E in Table 3 and Column E in Table 4.
SYSTEM 4: INTELLIGENCE FUNCTION 
Table 3 shows the groupings of agencies within the intelligence function, and it 
shows information exchange between System 4 and its environment.  Information 
for the biotechnology policy implementation is gathered from the following 
groups: 1) Industry players and all government ministries (by NIC) (NIC, 2010); 
2) International biotechnology communities, industry players and all government 
ministries (by BIOTEK, IAP and MIGHT); 3) International business communities, 
MOSTI units and researcher community (by MIDA, MITI, MIGHT, MASTIC 
and MOSTI); 4) Researcher and business communities (by BiotechCorp); 
5) BIOTEK and government research (by EPU).  In turn, several agencies help 
promote biotechnology policy to its environment.  Group 1 is not directly involved 
in promotion; Group 2, except IAP, promotes biotechnology policy to the general 
Malaysian public; Groups 3 and 4, promotes the biotechnology policy to foreign 
biotechnology investors; Groups 4 and 5 promotes the program to the general 
Malaysian public, and local biotechnology and general business communities.  All 
these indicate that the biotechnology policy already possesses a comprehensive 
intelligence function for its purpose, covering domestic as well as international 
arena.  These efforts are also well facilitated with BIOTEK functioning as the 
coordinator to the function. 
Subsystem 1: R&D, R&D Commercialization, Technology 
Development/Acquisition/ Transfer Services Subsystem
The clients of Subsystem 1 operating units are the entrepreneurs involved 
in biotechnology ventures or companies.  The environment also comprises 
supporting companies for the entrepreneurs, such as 1) private R&D institutes; 
2) private-operated R&D facilities that entrepreneurs can utilize to develop and 
commercialize their technologies; 3) private fund and financing providers, including 
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venture capitalists and angel investors that support technology development and/
or acquisition and/or commercialization by entrepreneurs and biotechnology 
companies; and 4) R&D units of private institutes of higher learning. 
It appears that the R&D operating units focused only on gathering scientific 
or R&D information that is directly related to their R&D activities.  Intelligence 
for other environmental elements, most importantly on their customers, is absent 
(indicated by the question mark symbol, on the line connecting Subsystem 1 to 
its environment).  These operating units rely on the information gathered by their 
management units.  For example, within Subsystem 1, many of the operating units 
are directly under MOSTI or under its purview, therefore, information regarding 
them are gathered mainly by BIOTEK on behalf of MOSTI.  Thus, their intelligence 
is mainly carried out through formal control hierarchical channel.  Some of their 
intelligence function is also taken up by the supporting functions in the R&D 
activities, such as MOSTI, BIOTEK, BiotechCorp and MTDC.
Subsystem 2: Firm Creation/Development Services Subsystem 
The clients of Subsystem 2 operating units are the BioNexus companies and other 
biotechnology companies, while their supporting companies include 1) private fund 
and financing providers, including banks, venture capitalists that provide financing/
funding to or make equity investments in biotechnology firms, and angel investors 
that support firm creation and development by entrepreneurs and biotechnology 
companies.  By 2010, there are about 30 venture capitalists in Malaysia and they 
provide funding to biotechnology firms at various development stages (MVCA, 
2010); 2)private-operated facilities; 3)private institutes of higher learning; and 4)
private firms that support IP protection and development.  These operating units 
conduct intelligence on their environment (indicated by the lines connecting the 
operating units to their environment).
Subsystem 3: Industry Development Services Subsystem
The clients of Subsystem 3 are the customers of biotechnology products and 
services and the general public.  Their supporting companies are 1) private-operated 
production/manufacturing facilities that entrepreneurs can utilize to develop and 
commercialize their technologies; 2) private fund and financing providers, which 
include banks, venture capitalists that provide financing/funding to or make equity 
investments in biotechnology firms, and angel investors that support firm creation 
and firm development by entrepreneurs and biotechnology companies; 3)private 
institutes of higher learning; and 4)private firms that support IP property protection 
and development.  These operating units conduct intelligence on their environment, 
(indicated by the lines connecting the operating units to their environment).
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Relationships Between the Control Function and Operating Units 
and Between the Operating Units of One Subsystem to Another 
Direct relationship between the control function and the operating units is absent 
as  indicated by the missing function of overall monitoring or direct “auditing” of 
operating units within Subsystem 1 (shown by the question mark symbol, on the 
line connecting Subsystems 1, 2 and 3 to System 3*).  Although there exist some 
intelligence gathering within the operating units at Subsystems 2 and 3, for example, 
BiotechCorp gathering information regarding BioNexus companies, and MTDC 
and MLSCF collecting information from the entrepreneurs and companies under 
their care via the RAIDAH platform, these information are perhaps not efficiently 
fed back into the control function due to the absence of monitoring function. 
Moreover, while there is some evidence of TPM conducting intelligence, most of 
the information are static and in the form of tenant directory.  Unlike  BiotechCorp 
and MTDC, TPM does not have an interactive system, except for its tenant online 
application system.
The  in and out arrows from one operating unit to another, as shown in Figure 
3, indicate that the operating units are directly related to one another.  Subsystem 2 
(firm creation/development) requires the output of Subsystem 1 (R&D), therefore, 
it is important that the operating units within Subsystem 1 are directly related to 
those in Subsystem 2.  Similarly, Subsystem 3 (industry development) depends on 
collective development of the biotechnology firms within Subsystem 2, therefore, 
requiring collaborations among the operating units of these two subsystems.  There 
is some evidence of direct relationships between an operating unit in Subsystem 1 
to an operating unit in Subsystem 2.  For example, UKM and MTDC in Subsystem 
1 progress together into Subsystem 2 through the MTDC Symbiosis Program.  In 
this case, UKM’s collaboration through the MTDC Symbiosis Program enables the 
technologies developed in UKM labs to be commercialized in the market place, 
through university spin-off companies.  This group of spin-off companies perhaps 
will progress to contributing to industry development in Subsystem 3.  Such a win-
win collaboration indicates synergistic relationships between the operating units. 
The operating units of the Subsystems are also connected through two important 
programs.  For example in the Agro subsystem, the Ministry of Agriculture and 
Agro-Industry (MOA) and the Federal Agricultural Marketing Authority (FAMA) 
co-organize the annual Malaysian Agriculture, Horticulture and Agrotourism 
Show (MAHA).  This event is organized not only to promote the agriculture and 
biotechnology-related sectors (intelligence function at the agro subsystem), but also 
to serve as the meeting place for those involved in the upstream (researchers and 
technology inventors community) and downstream activities (entrepreneurs and 
industry players) of the agro-biotechnology value chain (MOA, 2010).  Similar to 
MAHA, the BioMalaysia conference and exhibition also serves the same purpose, 
although the scope of this event covers nearly all types of biotechnology products 
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and services, rather than just agriculture (BioMalaysia 2010, 2010).  In this regard, 
BiotechCorp and MOSTI, which organize BioMalaysia, play an important role in 
connecting the operating units within System 1.
DISCUSSION
This study, which demonstrates the application of  VSM model in a thorough 
manner, enhances understanding on the use of the model, particularly in describing 
and explaining a policy implementation.  The comprehensive diagnosis of the policy 
implementation using VSM is supported by content analysis as the methodology and 
innovation theory as the main theoretical perspective.  The utilization of innovation 
theory provides the basis for the analysis, and supports the interpretation of study’s 
findings.  The use of the content analysis helps to provide structure to the process 
of defining and analyzing the data.  This helps achieve the objectives of the study 
as well as overcomes existing limitations within VSM studies, which generally 
do not lean on specific methodologies in their applications.  The demonstration of 
the full application of this model, which includes detailed explanation of all forms 
and lines within VSM, enhances the understanding of a systems model application. 
This approach in using VSM provides a practical guide to managers and policy 
makers in applying the model. 
The resulting mapping of the agencies’ and institutions’ functions onto VSM 
gives a clear picture about the Biotechnology Policy implementation.  First, the 
emergent model identifies the agencies and institutions that are directly involved 
in the implementation of the policy, as well as their functions and the relationships 
that exist among them.  This not only enables identification of the number of 
agencies involved, but also verification of whether the policy implementation system 
functions are congruence and incongruence with the VSM framework.  This also 
helps in identifying any missing functions or roles.  Second, the emergent model 
indicates which agencies are in the leading roles in the system.  For example, the 
emergent model shows that MOSTI and MOF act as the lead agencies in the meta-
systems (Systems 2 through 5), as well as in the policy implementation process 
(System 1).  MOSTI is directly involved in all subsystems of System 1, while MOF 
supports the entire operations through its role in the provision, distribution, and 
control of budgets.  Third, within the specific functions, the emergent model enables 
categorization of agencies according to the types of their roles (either in leading 
versus supporting, or as major versus minor roles), thus, further elaborates on their 
roles, functions, and inter-relationships.  Finally, the emergent model identifies 
horizontal relationships of the biotechnology policy implementation with its sister 
policy implementation (MSC Program). 
The above provides important implications for policy implementations. 
Information on the agencies’ functions and their relationships provided by VSM 
modeling allow each agency to identify its function vis-a-vis the policy and those 
88
International Journal of Economics and Management
of others.  Without this modeling, it is difficult for the units involved to get a clear 
picture of their functions and the relationships of their functions to others, and vice 
versa.  The identification of missing functions and the absence of the overall system 
monitoring and certain intelligence function provide important information to the 
system’s management in elaborating on their possible problems and developing 
appropriate solutions.  In fact, all the forms and lines in VSM underscores the 
workings of the policy implementation, and provide opportunities for clarification of 
functions and if needed, to proceed with rectification.  The emergent model, which 
also identifies relationships of the biotechnology policy implementation with its 
sister policy implementation, provides important venues for system improvement 
or design by policy decision makers.  As the study’s focus is only to demonstrate 
VSM application, the comprehensive interpretation of the emergent model is beyond 
the scope of the study.  These are reported in the second part of the study (Khairul 
Akmaliah, Hasmiah, Mohd Fuaad & Igel, 2010). 
As the utility and efficacy of VSM are shaped by the theoretical perspectives 
taken, identification of functions and problems is both facilitated and limited by the 
innovation theory, which is the perspective adopted in the study.  The innovation 
theory not only provides scope to the study, but also supports explanation and 
facilitates interpretation concerning the policy implementation system, which 
involves a technology-based industry.  These enable a more focused modeling and 
conceptualization to be achieved.  They also highlight to future researchers the 
importance of selecting appropriate theoretical perspectives that will serve the needs 
of the diagnosis and analysis of the system.  Application of VSM, however, demands 
good understanding on the philosophies and application of the model, as well as 
intimate knowledge on research phenomena.  It also requires interpretation by the 
researchers, which necessitates high analytical thinking and conceptualization. 
CONCLUSIONS
The application of VSM in this study provides to policy makers and implementers, 
the framework for diagnosis of future systems and important insights in the 
model application; both can help in improving their current systems or designing 
new ones.  However, successful improvement and design of a new system also 
requires information on its purpose.  For the researchers, on the other hand, they 
have an applicable theoretical conceptualization in describing and explaining 
research phenomena from a systems thinking perspective.  The study highlights 
that usage of VSM requires a) an in-depth understanding of the model’s concepts 
and philosophies, b) abilities to conceptualize the theoretical perspectives to 
provide scope and focus, as well as to assist in VSM modeling interpretation, and 
c) high analytical skills in model application and interpretation.  Thus, the use of 
VSM involves considerable time and efforts, and any future application requires 
substantial allocation of resources.
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APPENDIX A
Thrusts of Biotechnology Policy and Key Ministries In-Charged
Source: Refer to the sources in Tables 3 and 4.Additional sources are BioMalaysia (2010); FRIM 
(2010); MARDI (2010); MDTCC (2010); MNRE (2005, 2010); MOA (2010); MOH (2009; 2010); 
MOSTI (2005; 2010a); MPIC (2005; 2010); MPOB (2010); PMO (2005). See Appendix B for the full 
names of the ministries.
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APPENDIX B
List of Abbreviations (in alphabetical order)
No. Abbreviations Full Name
1 ABI Agro-Biotechnology Institute, Malaysia
2 AG Accountant General’s Department
3 BIC Biotechnology Implementation Council
4 BiotechCorp Malaysian Biotechnology Corporation Sdn Bhd
5 Cradle Fund Cradle Fund Sdn Bhd
6 CRDF Commercialization of R&D Funds
7 EPU Economic Planning Unit
8 FRIM Forest Research Institute of Malaysia
9 GENOMalaysia Malaysia Genome Institute
10 IAP International Advisory Panel
11 ICU Implementation Coordination Unit, Malaysia 
12 IMR Institute of Medical Research
13 InnoBio InnoBiologics Sdn. Bhd.
14 IPharm Malaysian Institute of Pharmaceuticals and Nutraceuticals
15 MAHA Malaysian Agriculture, Horticulture and Agrotourism 
Show
16 MARDI Malaysian Agriculture Research and Development 
Institute
17 MASTIC Malaysian Science and Technology Information Centre
18 MAVCAP Malaysia Venture Capital Management Bhd
19 MCB Malaysian Cocoa Board
20 MDTCC Ministry of Domestic Trade, Co-operatives and 
Consumerism
21 MDV Malaysia Debt Ventures Bhd.
22 MIDA Malaysian Industrial Development Authority
23 MIGHT Malaysian Industry-Government Group for High 
Technology
24 MITI Ministry of International Trade and Industry
25 MLSCF Malaysia Life Sciences Capital Fund
26 MNRE Ministry of Natural Resources and Environment
27 MOA Ministry of Agriculture & Agro-Based Industries
28 MOF Ministry of Finance
29 MOH Ministry of Health
30 MOHE Ministry of Higher Education
31 MOSTI Ministry of Science, Technology and Innovation
32 MPIC Ministry of Plantation Industries and Commodities
33 MPOB Malaysian Palm Oil Board
34 MRB Malaysian Rubber Board
35 MTDC Malaysian Technology Development Corporation
36 MSC Multimedia Super Corridor
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37 MVCA Malaysian Venture Capital and Private Equity 
Associations
38 MyIPO Intellectual Property Corporation of Malaysia
39 MyMDANA Integrated Fund Management System
40 NIC National Innovation Council
41 PMO Prime Minister’s Office
42 RAIDAH Research and Innovation Database Homepage
43 TAF Technology Acquisition Fund
44 TPM Technology Park Malaysia Corporation Sdn Bhd
45 TPM Biotech TPM Biotech Sdn Bhd
46 UEM Land UEM Land Holdings Berhad
47 VSM Viable System Model
